Express Pharma
NOVEMBER 21, 2024
Additionally, it is approved in the EU for gMG and in Japan for gMG and primary immune thrombocytopenia (ITP) under brand names Vyvgart and Vyvdura. per cent from 56,009 in 2023 to 56,163 in 2027.
pharmaphorum
JANUARY 10, 2023
Other IgG proteases are being developed to tackle the issue of pre-existing immunity against AAV, but according to Selecta chief executive Carsten Brun these tend to be derived from common human pathogens – which means they themselves can be the target of existing antibodies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 19, 2023
The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition.
European Pharmaceutical Review
MAY 4, 2023
According to Research and Markets 8 , the market for bispecific antibodies for cancer is forecasted to grow by $400 million during 2022-2027, due to the increasing prevalence of cancer worldwide. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity.
pharmaphorum
JANUARY 17, 2023
Its vocal biomarkers are already being used to gauge the effect of drug treatments for dementia, including in the phase 2 TAURIEL trial of Roche/AC Immune’s’s tau protein-targeted antibody semorinemab. million) to its top-line in 2023 with “considerable growth” next year.
Express Pharma
SEPTEMBER 12, 2023
tumor formation, immune reactions, and therapy failure). HepaStem is projected to hit the US market in Q1 2027, while BioVie’s BIV201 is anticipated to be marketed in Q4 2028. Albutein appears to be on track to be the first therapeutic approved for DC, with a projected US launch date in Q1 2026.
European Pharmaceutical Review
FEBRUARY 22, 2023
1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027.
Expert insights. Personalized for you.
96 
Let's personalize your content